Bellerophon Therapeutics, Inc. (BLPH) stock prices updated...
 

Bellerophon Therapeutics, Inc. stock price

Bellerophon Therapeutics, Inc. latest news:


  • 11/07/2017 07:04:41

    BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

    Bellerophon Therapeutics Inc(BLPH). * Bellerophon provides business update and reports third quarter 2017 financial results. * Q3 loss per share $0.22. * Says ‍ phase 2a study for inopulse met its primary endpoint​ Source text for Eikon: Further company coverage:

  • 10/24/2017 15:26:27

    BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

    Bellerophon Therapeutics Inc(BLPH). * Bellerophon Therapeutics Inc(BLPH) files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing. * Bellerophon Therapeutics Inc (BLPH) - the selling stockholders will receive all of the proceeds from any sales of the shares offered Source text: Further company coverage:

  • 09/05/2017 06:40:17

    Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment

    Bellerophon Therapeutics Inc. shares surged 20% in premarket trade, after the company reported positive results in a mid-stage trial of a treatment for pulmonary hypertension associated with chronic obstructive pulmonary disease. The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume. "COPD patients with associated pulmonary hypertension have a poor prognosis with an approximately 4-year life expectancy and high hospitalization rates, which represents a significant unmet medical need for a safe and effective long-term treatment," said Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA and Chairman of Bellerophon's PH-COPD steering committee. The company is planning to conduct a larger phase 2b study of the treatment. Shares have gained 117% in 2017, while the S&P 500 has gained 10.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Bellicum Pharmaceuticals, Inc.BLCM | Beneficial Bancorp, Inc.BNCL | Benefitfocus, Inc.BNFT | Benitec Biopharma LimitedBNTC | Benitec Biopharma LimitedBNTCW | BG Medicine, Inc.BGMD | BGC Partners, Inc.BGCP | Big 5 Sporting Goods CorporationBGFV | BIND Therapeutics, Inc.BIND | Bio Blast Pharma Ltd.ORPN |